A multi-center continuation trial for patients completing study M02-518 and M02-570 of the human anti-TNF [tumour necrosis factor] monoclonal antibody adalimumab (D2E7) in patients with moderate to severely active psoriatic arthritis

Trial Profile

A multi-center continuation trial for patients completing study M02-518 and M02-570 of the human anti-TNF [tumour necrosis factor] monoclonal antibody adalimumab (D2E7) in patients with moderate to severely active psoriatic arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 28 May 2011

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms ADEPT
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 28 May 2011 Disease progression outcomes according to baseline skin disease presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 28 Aug 2007 Status changed from in progress to completed.
    • 14 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top